Preferred Label : Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA;
NCIt synonyms : Anti-TAG ARC-T Cells Directed by BCMA Bi-valent/TAG SparX Protein; Immunotherapeutic Combination Agent SparX Protein Plus CART-ddBCMA; TAG-containing SparX /Bivalent BCMA-targeted ARC-T Cells; ARC-T Plus Anti-BCMA SparX;
NCIt definition : An immunotherapeutic combination agent composed of antigen receptor complex T cells
(ARC-T cells) which contain a proprietary binding domain specific for a universal
TAG instead of a single chain variable fragment (scFv) binding domain, and a tumor-targeting
antigen protein, soluble protein antigen-receptor X-linker (sparX) protein, containing
a TAG moiety fused to two B-cell maturation antigen (BCMA; tumor necrosis factor receptor
superfamily member 17; TNFRSF17) binding domains, with potential antineoplastic activities.
Upon administration of the anti-BCMA sparX protein plus BCMA-directed ARC T-cells
CART-ddBCMA, the sparX protein, with its two BCMA binding domains, specifically targets
and binds to two BCMA expressed on tumor cells. In turn, the ARC-T cells, with their
anti-TAG domain, target and bind to the TAG domain on the sparX protein. This directly
links the ARC-T cells to the BCMA-expressing tumor cells, through the ARC-T cell-
sparX -tumor cell complex formation, thereby causing direct tumor cell killing. BCMA,
a tumor-associated antigen (TAA), is found on the surfaces of plasma cells and is
overexpressed on a variety of tumor cell types. Compared to anti-BCMA CAR-T cells,
CART-ddBCMA, containing ARC-T cells that are re-programmed in vivo by the TAG sparX
protein, shows enhanced efficiency and an improved safety profile. As ARC-T activity
is dependent on the sparX dose administered, the rate of tumor cell killing, and related
toxicities are also dependent on the sparX dose administered.;
NCI Metathesaurus CUI : CL972316;
Origin ID : C167337;
UMLS CUI : C5238473;
Semantic type(s)
- concept_is_in_subset
- has_target
